J:NYSEJacobs Solutions Inc. Analysis
Data as of 2026-03-11 - not real-time
$131.84
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Jacobs Solutions is trading below its 20‑day and 50‑day simple moving averages, both of which sit under the 200‑day average, signaling a sustained bearish bias. The 14‑day RSI around the low‑40s and a MACD histogram that remains negative reinforce the short‑term downside momentum, while volume has been trending lower, suggesting waning buying interest. Despite the technical weakness, the stock carries a high 30‑day volatility of nearly 48% and a beta close to one, indicating it moves roughly in line with the market but with amplified swings. Fundamentals paint a more optimistic picture: revenue is expanding at double‑digit rates, forward earnings are projected to more than double the trailing EPS, and the discounted cash‑flow model implies a fair value roughly 19% higher than the current price. The price‑to‑earnings multiple sits above the industry average, yet the dividend yield of just over 1% is supported by a modest payout ratio and solid free cash flow, making the dividend sustainable. Recent contract wins in the U.K. infrastructure sector provide a tangible catalyst that could lift top‑line growth. Overall, the company sits at the intersection of a growth‑oriented earnings outlook and a value‑type discount, with a dividend that adds a modest income buffer. Investors should weigh the near‑term technical headwinds against the longer‑term upside embedded in the valuation and the company’s diversified global footprint.
Given the mix of high volatility, bearish technicals, and a clear upside thesis from the DCF and contract pipeline, the stock may be best approached with a patient stance, holding through the short‑term dip while positioning for a rebound as fundamentals reassert themselves.
Given the mix of high volatility, bearish technicals, and a clear upside thesis from the DCF and contract pipeline, the stock may be best approached with a patient stance, holding through the short‑term dip while positioning for a rebound as fundamentals reassert themselves.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish technical indicators (SMA crossover, MACD, RSI)
- Proximity to identified support level
- Potential upside from valuation gap
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Strong revenue growth and improving forward EPS
- Recent multi‑year contract win in the U.K.
- Sustainable dividend with solid cash flow
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF‑derived upside of roughly 19%
- Diversified global client base reducing concentration risk
- Consistent dividend and attractive return on equity
Key Metrics & Analysis
Financial Health
Revenue Growth12.30%
Profit Margin3.50%
P/E Ratio34.9
ROE9.73%
ROA5.68%
Debt/Equity65.17
P/B Ratio4.5
Op. Cash Flow$960.0M
Free Cash Flow$1.1B
Industry P/E29.4
Technical Analysis
TrendBearish
RSI41.5
Support$126.03
Resistance$153.08
MA 20$137.29
MA 50$138.01
MA 200$141.30
MACDBearish
VolumeDecreasing
Fear & Greed Index76.91
Valuation
Fair Value$203.20
Target Price$157.53
Upside/Downside19.49%
GradeUndervalued
TypeBlend
Dividend Yield1.09%
Risk Assessment
Beta0.95
Volatility47.92%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.